"Our study provides one of the first national estimates of the decline in utilization of bariatric metabolic surgery among privately insured patients corresponding to the rising use of blockbuster ...
It found that between 2022 and 2023, as prescriptions for GLP-1 drugs more than doubled, rates of bariatric surgery fell by 25.6%. The findings, published Wednesday in JAMA Network Open ...
A new study from Northwestern University indicates that GLP-1s (the active ingredient in weight loss medications) will hit most patients much harder financially than bariatric surgery will.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback